Experience

Lucid Health Consulting - Experience Matters.

• Australia
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director and Partner

  • Jan 2016 - Present

  Specialising in:– health technology assessment for reimbursement/submission preparation for medicines, biotechnology and medical devices– pricing strategy, including negotiations and price defence– market access including advisory boards, commercial assessments and stakeholder mapping Lucid Health Consulting is founded in 2016 by the three directors, George Papadopoulos, Michael Aristides and Steve Crowley, each with over 25 years experience across the areas of health economics and market access. The directors are supported by an extended team with a proven track record in medical writing, biostatistics, economic modelling and medical information. The strength of Lucid Health Consulting is demonstrated by the quote from Aristotle, “the whole is greater than the sum of its parts”. By joining forces, the directors of Lucid Health Consulting each contribute their expertise to a project, resulting in a more comprehensive and ultimately more successful outcome. The directors maintain a ‘hands-on’ approach, leading every project and acting as the key point of contact to provide seamless project management. We truly believe that “Experience Matters”..Lucid Health Consulting provides expertise in health economics, health technology assessments, pricing and reimbursement strategy. LHC provides clients with comprehensive HTA packages and submissions along with in depth commercial and reimbursement feasibility assessments. Lucid Health Consulting has prepared submissions for a range of advisory committees including PBAC, MSAC, PHARMAC, SMC, NICE and support packages in other European countries and Asia Pacific. Lucid Health Consulting has worked across a range of therapeutic areas including oncology, cardiovascular, CNS, Infectious Diseases and Immunology.Lucid Health Consulting has offices located in Sydney, Melbourne, Perth and San Diego.



S& J Crowley Consulting Pty Ltd

• Director

  • Nov 2015 - Present

  Reimbursement, pricing and market access consultant for Australia and Asia-Pacific Reimbursement, pricing and market access consultant for Australia and Asia-Pacific



The Janssen Pharmaceutical Companies of Johnson & Johnson

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Executive Director, Integrated Market Access

  • Sep 2010 - Oct 2015

  This position brings together in a single department many of the functions that support pre-launch activities for a new product including: early and new product development, business development, regulatory affairs, health economics and pricing, and corporate and government affairs. Key activities & milestones include:- establishment of integrated department, an approach that has now been emulated in multiple Asia-Pacific markets- introduction of new early and new product commercialisation processes- development of real world evidence processes and capabilities- introduction of formal stakeholder mapping processes- establishment of Integrated Market Access Centre of Excellence to support training of Asia-Pacific capabilities in market accessWithin Asia-Pacific region- team leader of cardiovascular-metabolic TASTe, regional cross-functional team- review of Janssen Japan early and new product introduction processes leading to establishment of Integrated Market Access department- team leader in developing a Asia Pacific regional cross-functional approach to generation of real world evidence to support market access and commercialisation of new products



University of Melbourne

• Australia
• Higher Education
• 700 & Above Employee

• Senior Lecturer

  • Jan 2005 - Dec 2014

  The part-time position within the Centre for Health Policy, Programs and Economics Melbourne School of Population Health involves coordinating and teaching 2 units in Economic Evaluation to Masters of Public Health Students. Many of the students are from a variety of countries including Australia, Asia and Africa. The part-time position within the Centre for Health Policy, Programs and Economics Melbourne School of Population Health involves coordinating and teaching 2 units in Economic Evaluation to Masters of Public Health Students. Many of the students are from a variety of countries including Australia, Asia and Africa.



S&J Crowley Consulting

• Director

  • Apr 2009 - Sep 2010

  Consulting services provided included: advice on reimbursement and pricing strategies including internal and external stakeholder alignment and management; advice on reimbursement and pricing strategies and processes for both Australia and Asia-Pacific region )focus on Japan) for both pharmaceuticals and device sectors; development of policy positions and papers in relation to HTA.Consultancies included:- drafting a White Paper and providing training for global medical device organisation- writing proposal on behalf of industry association to the Australia government's review of health technology assessment- reviewing best practice in market access processes, structures and capabilities to inform global device company on ideas to improve approached to building market access capabilities- review of impact of PBS reform in Australia on the Victorian pharmaceutical industry- development of a framework and template for a device company for use when assessing reimbursement and pricing issues for licencing and acquisition opportunities- drafting an issues paper for the funding of biologics and targeted therapies for an Australian affiliate of a biotech company- establishment of a database and training material on health and non-health data sources used for reimbursement and pricing submissions to the PBAC in Australia- undertaking multiple feasibility proposals for companies wanting to achieve future reimbursement of products in Japan



Janssen Cilag Asia Pacific

• Director, Market Access, Asia Pacific

  • Mar 2007 - Apr 2008

  The role focused on building and coordinating health economic, pricing and wider market access capabilities in the Asia-Pacific region. Focus was on countries that have or will be introducing health technology assessment and cost-effectiveness as part of government reimbursement. In this role I was a member of the Asia-Pacific Management Team and had dual reporting to the regional International VP and the Global head of Health Economics and Pricing. The role focused on building and coordinating health economic, pricing and wider market access capabilities in the Asia-Pacific region. Focus was on countries that have or will be introducing health technology assessment and cost-effectiveness as part of government reimbursement. In this role I was a member of the Asia-Pacific Management Team and had dual reporting to the regional International VP and the Global head of Health Economics and Pricing.



Janssen Cilag Australia

• Executive Director, Health Economics, Pricing & Market Access

  • Sep 2002 - Mar 2007

  The position was on the Australian management team and I was head of the department that was responsible for achieving reimbursement and pricing for products on the Pharmaceutical Benefits Scheme (PBS). The department also included a market access function which was responsible for coordinating early and new product development activities across the company. The position was on the Australian management team and I was head of the department that was responsible for achieving reimbursement and pricing for products on the Pharmaceutical Benefits Scheme (PBS). The department also included a market access function which was responsible for coordinating early and new product development activities across the company.



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Manager

  • 2000 - 2000

  The role was head of health economics and pricing within the Healthcare Strategies and Corporate Affairs directorate. The position involved rebuilding the reimbursement, health economics and pricing capabilities with a focus on improving the external focus of the company and improving stakeholder relationships. Formal stakeholder feedback from industry association, government and other key organisations showed significant improvement with the company perceived as having industry best practice in many key areas considered important by these stakeholders. While in this role I was very active in industry association activities which provided key learnings on the healthcare and reimbursement environment in Australia.



Glaxo Wellcome

• Health Economics Manager

  • 1997 - 2000

  This position involved providing reimbursement support for key therapeutic areas. My area of expertise at the company was developing health economic models for PBAC submissions in addition to being responsible for developing decision analytic models for the global organisation in the areas of hepatitis B, asthma and gastroenterology. In addition, the role provided opportunities to be involved in early product feasibility analyses. This position involved providing reimbursement support for key therapeutic areas. My area of expertise at the company was developing health economic models for PBAC submissions in addition to being responsible for developing decision analytic models for the global organisation in the areas of hepatitis B, asthma and gastroenterology. In addition, the role provided opportunities to be involved in early product feasibility analyses.



S&J Crowley Nutrition Consultants

• Director

  • 1983 - 1988

  Provided nutrition and dietetic services to a range of private hospitals and consulting rooms in the northern suburbs of Melbourne in addition to consultancy at defence forces (both army at Puckapunyal and Navy at HMAS Cerebres). Provided nutrition and dietetic services to a range of private hospitals and consulting rooms in the northern suburbs of Melbourne in addition to consultancy at defence forces (both army at Puckapunyal and Navy at HMAS Cerebres).